{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:25:20Z","timestamp":1780374320121,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00277-022-05011-6","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T09:02:57Z","timestamp":1668243777000},"page":"429-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of pre- and\/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-7306","authenticated-orcid":false,"given":"Carmen","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Espeso","family":"de Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domingo-Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Zeberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Paz","family":"Mart\u00ednez-Badas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Rodr\u00edguez-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Vallansot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"D\u00edaz-G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Torrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Grupo Espa\u00f1ol de Linfoma y Trasplante de M\u00e9dula \u00d3sea (GELTAMO) y Grupo Espa\u00f1ol de Trasplante (GETH)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"5011_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomized trial. Lancet 341:1051\u20131054","journal-title":"Lancet"},{"key":"5011_CR2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensory Hodgkin\u2019s disease: a randomized trial. Lancet 359:2065\u20132071","journal-title":"Lancet"},{"key":"5011_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","volume":"21","author":"MA Perales","year":"2015","unstructured":"Perales MA, Ceberio I, Armand P et al (2015) Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 21:971\u2013983","journal-title":"Biol Blood Marrow Transplant"},{"key":"5011_CR4","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P et al (2019) Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant 54:1525\u20131552","journal-title":"Bone Marrow Transplant"},{"key":"5011_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE et al (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transpl 12:1065\u20131072","journal-title":"Biol Blood Marrow Transpl"},{"key":"5011_CR6","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","volume":"19","author":"T Hahn","year":"2013","unstructured":"Hahn T, McCarthy PL, Carreras J et al (2013) Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transpl 19:1740\u20131744","journal-title":"Biol Blood Marrow Transpl"},{"key":"5011_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A et al (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma auto grafted after a first relapse. Ann Oncol 16:625\u2013633","journal-title":"Ann Oncol"},{"key":"5011_CR8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665\u20131670","journal-title":"Blood"},{"key":"5011_CR9","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bmt.2017.143","volume":"52","author":"M Damlaj","year":"2017","unstructured":"Damlaj M, Ghazi S, Syed G et al (2017) Pre-autologous transplantation PET\/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant 52:1342\u20131344","journal-title":"Bone Marrow Transplant"},{"key":"5011_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, AETHERA Study Group et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853\u20131862","journal-title":"Lancet"},{"key":"5011_CR11","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A et al (2018) Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132:2639\u20132642","journal-title":"Blood"},{"key":"5011_CR12","unstructured":"Seattle Genetics, Inc. ADCETRISVR (brentuximab vedotin) for injection. Full prescribing information. Food and Drug Administration. Available at: http:\/\/www.seattlegenetics.com\/pdf\/adcetris_USPI.pdf [Last accessed 20 Jan 2017]"},{"key":"5011_CR13","unstructured":"Takeda Pharma A\/S. ADCETRISVR 50 mg powder for concentrate for solution for infusion. Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/002455\/WC500135055.pdf [Last accessed 20 Jan 2017]"},{"key":"5011_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2939","volume":"40","author":"F Massaro","year":"2022","unstructured":"Massaro F, Pavone V, Stefani PM et al (2022) Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience. Hematol Oncol 40:31\u201339","journal-title":"Hematol Oncol"},{"key":"5011_CR15","doi-asserted-by":"publisher","unstructured":"Marouf A, Cottereau AS, Kanoun S et al (2021) Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2021.279564. Online ahead of print","DOI":"10.3324\/haematol.2021.279564"},{"key":"5011_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/hon.2897","volume":"39","author":"OM Akay","year":"2021","unstructured":"Akay OM, Ozbalak M, Pehlivan M et al (2021) Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. Hematol Oncol 39:498\u2013505","journal-title":"Hematol Oncol"},{"key":"5011_CR17","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1038\/s41409-020-0935-0","volume":"55","author":"M Damlaj","year":"2020","unstructured":"Damlaj M, Abuelgasim KA, Alhejazi A et al (2020) Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant 55:2322\u20132325","journal-title":"Bone Marrow Transplant"},{"key":"5011_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on Lymphoma et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"5011_CR19","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"5011_CR20","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.bbmt.2018.05.026","volume":"24","author":"A Nademanee","year":"2018","unstructured":"Nademanee A, Sureda A, Stiff P et al (2018) Safety analysis of brentuximab vedotin from the phase III AETHERA trial in Hodgkin lymphoma in the post-transplant consolidation setting. Biol Blood Marrow Transplant 24:2354\u20132359","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05011-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05011-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05011-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:06:14Z","timestamp":1675155974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05011-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5011"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05011-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"17 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.M. declares consultancy for and honoraria from Takeda and Bristol Myers Squibb; M.E.H. declares honoraria from Takeda, Roche, Janssen, Kite\/Gilead, Amgen, Pfizer, EusaPharma, and Servier; S.R. declares honoraria from Takeda; E.D.D. has received honoraria from Takeda and Bristol Myers Squibb; A.P.G.R. declares consultancy for and honoraria from Takeda; I.Z. declares consultancy for and honoraria from Takeda; M.P.M.B. declares honoraria from Takeda; A.R.I. declares honoraria from Takeda; C.C. declares honoraria and\/or non-financial support from Takeda, Regeneron, Novartis, and Bristol Myers Squibb; J.A.H.R. declares consultancy for and speaker\u2019s bureau from Takeda; R.G.S. declares research support by the Spanish National Healthy System, Regional Healthy System (<i>Castilla y Le\u00f3n<\/i>), <i>Asociaci\u00f3n Espa\u00f1ola Contra el Cancer<\/i> (AECC), Takeda, Gilead, Astellas, honoraria from Amgen, Millennium\/Takeda, Janssen, Incyte, Astellas, BeiGene, Astra Zeneca, Pfizer, and Speakers Bureau\/Scientific Advisory Board for Amgen, Pharmacyclics, Millennium\/Takeda. F.J.D.G., M.B., R.V., N.K., and T.T. declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}